1. Evaluation of the immunogenicity of a recombinant HSV-1 vector expressing human group C rotavirus VP6 protein.
- Author
-
Rota RP, Palacios CA, Temprana CF, Argüelles MH, Mandile MG, Mattion N, Laimbacher AS, Fraefel C, Castello AA, and Glikmann G
- Subjects
- Animals, Antibodies, Viral immunology, Chlorocebus aethiops, Humans, Immunity, Humoral, Male, Mice, Phylogeny, Recombinant Proteins, Vero Cells, Antigens, Viral genetics, Antigens, Viral immunology, Capsid Proteins genetics, Capsid Proteins immunology, Gene Expression, Genetic Vectors genetics, Herpesvirus 1, Human genetics, Rotavirus genetics, Rotavirus immunology
- Abstract
Group C Rotavirus (RVC) has been associated globally with sporadic outbreaks of gastroenteritis in children and adults. RVC also infects animals, and interspecies transmission has been reported as well as its zoonotic potential. Considering its genetic diversity and the absence of effective vaccines, it is important and necessary to develop new generation vaccines against RVC for both humans and animals. The aim of the present study was to develop and characterize an HSV-1-based amplicon vector expressing a human RVC-VP6 protein and evaluate the humoral immune response induced after immunizing BALB/c mice. Local fecal samples positive for RVC were used for isolation and sequencing of the vp6 gene, which phylogenetically belongs to the I2 genotype. We show here that cells infected with the HSV[VP6C] amplicon vector efficiently express the VP6 protein, and induced specific anti-RVC antibodies in mice immunized with HSV[VP6C], in a prime-boost schedule. This work highlights that amplicon vectors are an attractive platform for the generation of safe genetic immunogens against RVC, without the addition of external adjuvants., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF